AIM ImmunoTech commits $1.5 million to Ampligen drug substance batches in Sterling Pharma pact
In focus: AIM ImmunoTech (NYSE American: AIM) and a July 31, 2026, Proposal Agreement with contract manufacturer Sterling Pharma Solutions that commits approximately $1.5 million over 12 months to produce fresh batches…
Key takeaways
- AIM ImmunoTech committed approximately $1.5 million over 12 months to have Sterling Pharma Solutions produce fresh batches of the polynucleotide drug substances PolyI and Poly C12U under a July 31, 2026 Proposal Agreement.
- The batches, made at Sterling's Dudley, UK facility, supply the polymer precursors for Ampligen, AIM's experimental drug candidate, along with transfer of associated test methods.
- AIM intends to use the Sterling-manufactured material for ongoing and future clinical trials, including a potential Phase 3 study in metastatic pancreatic cancer, though no Phase 3 start date or protocol details were disclosed.
- The 8-K disclosing the agreement was filed August 6, 2026, signed by CEO Thomas K. Equels, with the full Proposal Agreement attached as Exhibit 10.1.
- The agreement builds on a 2022 relationship in which AIM and Sterling signed a Master Service Agreement and a Quality Agreement.
In focus: AIM ImmunoTech (NYSE American: AIM) and a July 31, 2026, Proposal Agreement with contract manufacturer Sterling Pharma Solutions that commits approximately $1.5 million over 12 months to produce fresh batches of the polynucleotide drug substances PolyI and Poly C12U at Sterling's Dudley, UK facility. The manufactured output feeds the polymer precursor chain for Ampligen, AIM's experimental drug candidate. The next confirmable milestone is whether that batch production, and the transfer of associated test methods, come in on the 12-month schedule the agreement describes.
The manufacturing commitment
The Proposal Agreement builds on a relationship formalized in 2022, when AIM ImmunoTech and Sterling Pharma Solutions signed both a Master Service Agreement and a Quality Agreement. Under the new terms, Sterling takes on production of PolyI and Poly C12U and handles the transfer of associated test methods at its Dudley site. The $1.5 million figure is the company's own estimate, spread across the payment schedule set out in the agreement.
The polynucleotide drug substances sit at the upstream end of the Ampligen supply chain. PolyI and Poly C12U are the polymer precursors the finished drug requires, so batch yield and test-method transfer at Dudley feed directly into AIM's clinical timeline before the product ever reaches a trial site.
The clinical intent
AIM ImmunoTech states its intention to use the Sterling-manufactured material for ongoing and future clinical trials, with specific mention of a potential Phase 3 study in metastatic pancreatic cancer. The Phase 3 language carries a qualifier built into the filing: "potentially." No Phase 3 start date, enrollment target, or protocol structure appears in the 8-K. The tape gets those details only when a definitive agreement or regulatory filing surfaces.
What to watch
The 8-K was filed August 6, 2026, and signed by CEO Thomas K. Equels, with the full Proposal Agreement attached as Exhibit 10.1. Separately, the filing establishes director nomination deadlines for the 2026 annual meeting: stockholder notices must reach AIM ImmunoTech between August 18 and September 17, 2026, with submissions under universal proxy rules due by October 19, 2026. The physical check on the Ampligen setup is straightforward: batch production and test-method transfer at Dudley, on the 12-month clock, starting July 31.